title: The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer.
abstract: OBJECTIVE
  There is no regimen that is strongly recommended for more than second-line treatment. We investigated the efficacy and safety of platinum/vinorelbine as more than second-line treatment.
  
  
  METHODS
  We selected patients with advanced non-small cell lung cancer (NSCLC) who received treatment with platinum/vinorelbine at Chungnam National University Hospital from August 2001 to December 2013. The primary end point was the response rate, and secondary end points were progression-free survival (PFS), overall survival (OS), and toxicity.
  
  
  RESULTS
  Thirty-five patients were enrolled. Response rate was 22.9% (complete response, 0 patients [0%]; partial response, eight patients [22.9%]; stable disease, 10 patients [28.6%]; progressive disease, 14 patients [40.0%]). A significantly higher response rate was observed for patients who had responded to previous chemotherapy than for those who did not (34.8% [8/23] vs. 0% [0/12], p=0.020). The median PFS was 4 months (range, 1 to 21 months). Patients with adenocarcinoma and non-smokers had a significantly longer PFS than patients with non-adenocarcinoma and smokers (5 months vs. 2 months, p=0.007; 4.5 months vs. 2 months, p=0.046, respectively). The median OS was 10 months (range, 1 to 41 months). Patients with good performance status and non-smokers had a significantly longer OS than patients with poor performance status and smokers (14 months vs. 4 months, p=0.02; 18.5 months vs. 6 months, p=0.049, respectively). The main serious adverse event (grade 3 or 4) was neutropenia (15 events, 13.3%) in a total of 113 cycles.
  
  
  CONCLUSIONS
  Platinum/vinorelbine was effective as more than second-line chemotherapy, and the toxicity was tolerable, in patients with advanced NSCLC.
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
authors.forename: Ik-Chan
authors.initials: IC
authors.lastname: Song
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
authors.forename: Hyo-Jin
authors.initials: HJ
authors.lastname: Lee
authors.affiliation: Department of Internal Medicine, Daejeon St. Mary's Hospital, Daejeon, Korea.
authors.forename: Young-Jun
authors.initials: YJ
authors.lastname: Yang
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
authors.forename: Yoon-Seok
authors.initials: YS
authors.lastname: Choi
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
authors.forename: Hye-Won
authors.initials: HW
authors.lastname: Ryu
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
authors.forename: Myung-Won
authors.initials: MW
authors.lastname: Lee
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
authors.forename: Ji Young
authors.initials: JY
authors.lastname: Moon
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
authors.forename: Deog-Yeon
authors.initials: DY
authors.lastname: Jo
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
authors.forename: Samyong
authors.initials: S
authors.lastname: Kim
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
authors.forename: Hwan-Jung
authors.initials: HJ
authors.lastname: Yun
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010984:Platinum / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology*; D012189:Retrospective Studies; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D000077235:Vinorelbine
chemical_list: D010984:Platinum; D014747:Vinblastine; D000077235:Vinorelbine
keywords: Drug therapy; Non-small-cell lung carcinoma; Third-line treatment